Alder lands $40M in third round

With the help of Delphi Ventures and TPG Biotech, Bothell, WA-based Alder Biopharmaceuticals gained $40 million in its third round round of financing. Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital also contributed to the round. Alder identifies, develops, and manufactures antibody therapeutics to treat autoimmune and inflammatory diseases.

"This financing will allow Alder to rapidly advance our lead antibody therapeutic ALD518 through multiple proof-of-concept trials, broaden our product pipeline, and continue to build on our proprietary antibody discovery and manufacturing technologies."

- see this release for more

ALSO: California-based ViOptix raised $12.2 million in a Series D round of financing. Report

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.